News of Note—New CRISPR R&D head; Homology $83.5M raise; Cellectar collab – FierceBiotech
FierceBiotech |
News of Note—New CRISPR R&D head; Homology $83.5M raise; Cellectar collab
FierceBiotech After jumping ship from a troubled AstraZeneca, its former head of oncology, Tony Ho, M.D., has climbed aboard preclinical gene editing biotech CRISPR Therapeutics. He becomes EVP and head of R&D at the company and will oversee its global research … |
